ar

A unique collection of 631 nuclear receptor signaling targeted compounds for high throughput and high content screening;

The Chemdiv covalent inhibitor library contains a diverse range of structurally unique and novel covalent binding compounds, with a total of over 12,000 compounds, and is continuously expanding. It is an essential tool for covalent inhibitor research.

A unique collection of 2960 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3400 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

Well-chosen 1360 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 610 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with PI3K/Akt/mTOR signaling;

Well-chosen 898 compounds with unique structures targeting transcription factor;

A unique collection of 2400 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 2955 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 1385 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 9332 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2680 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 3230 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 1000 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.

A unique collection of 653 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 540 gut microbial metabolites which can be used for HTS and HCS;

A unique collection of 3059 metabolic pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A unique collection of 5100 human metabolites for high-throughput, high-content screening.

A unique collection of 2154 compounds related to neurodegenerative diseases can be used for HTS or HCS;

A unique collection of 3550 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS);